113 related articles for article (PubMed ID: 38377560)
21. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
Yin L; Li H; Liu W; Yao Z; Cheng Z; Zhang H; Zou H
Eur J Med Chem; 2018 Jan; 144():1-28. PubMed ID: 29247857
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and antitumor activity of novel thiophene- triazine derivatives bearing arylurea unit as potent PI3K/mTOR inhibitorss.
Xu S; Luo L; Sun X; Yang Y; Guo Q; Jiang Z; Wu Y
Bioorg Med Chem; 2023 Jan; 78():117133. PubMed ID: 36599263
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, Antitumor Activity and Molecular Docking Studies on Seven Novel Thiazacridine Derivatives.
Almeida ML; Viana DCF; da Costa VCM; Dos Santos FA; Pereira MC; Pitta MGR; de Melo Rêgo MJB; Pitta IR; Pitta MGR
Comb Chem High Throughput Screen; 2020; 23(5):359-368. PubMed ID: 32189590
[TBL] [Abstract][Full Text] [Related]
24. Discovery of New Quinazoline Derivatives as VEGFR-2 Inhibitors: Design, Synthesis, and Anti-proliferative Studies.
Dhawale SA; Dabhade PS; Mokale SN
Anticancer Agents Med Chem; 2023; 23(18):2042-2055. PubMed ID: 37455449
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Bioactivity Evaluation of Novel Rosin Diterpenoid Derivatives as Potential Anti-glioma Agents.
Ou J; Tan W; Chen G; Yang X; Luo Y; Jin X; Ye L
Chem Biodivers; 2023 Aug; 20(8):e202300942. PubMed ID: 37485637
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 3-Cinnamamido-N-Substituted Benzamides as Potential Antimalarial Agents.
Liu H; Futamura Y; Wu H; Ishiyama A; Zhang T; Shi T; Zheng Q; Iwatsuki M; Ōmura S; Zou H; Osada H
Med Chem; 2021; 17(10):1207-1218. PubMed ID: 32807065
[TBL] [Abstract][Full Text] [Related]
27. Design, Synthesis and in Vitro Tumor Cytotoxicity Evaluation of 3,5-Diamino-N-substituted Benzamide Derivatives as Novel GSK-3β Small Molecule Inhibitors.
Zhou Y; Zhang L; Fu X; Jiang Z; Tong R; Shi J; Li J; Zhong L
Chem Biodivers; 2019 Sep; 16(9):e1900304. PubMed ID: 31338947
[TBL] [Abstract][Full Text] [Related]
28. Discovery of benzamide-based PI3K/HDAC dual inhibitors with marked pro-apoptosis activity in lymphoma cells.
Deng J; Hou B; Hou X; Chen Y; Zhang T; Chen H; Wang Y; Li X
Eur J Med Chem; 2023 Dec; 262():115915. PubMed ID: 37948955
[TBL] [Abstract][Full Text] [Related]
29. A Dual Receptor Targeting- and BBB Penetrating- Peptide Functionalized Polyethyleneimine Nanocomplex for Secretory Endostatin Gene Delivery to Malignant Glioma.
Lu L; Chen H; Wang L; Zhao L; Cheng Y; Wang A; Wang F; Zhang X
Int J Nanomedicine; 2020; 15():8875-8892. PubMed ID: 33209022
[TBL] [Abstract][Full Text] [Related]
30. Discovery of N-(2-Amino-4-Fluorophenyl)-4-[
Chen Y; Feng J; Hu Y; Wang X; Song W; Zhang L
Front Oncol; 2020; 10():592385. PubMed ID: 33178617
[TBL] [Abstract][Full Text] [Related]
31. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 2-ethoxy-4-(methoxymethyl)benzamide derivatives as potent and selective PTP1B inhibitors.
Xie F; Liang Y; Xia Y; Luo S; Jiang F; Fu L
Bioorg Chem; 2019 Nov; 92():103273. PubMed ID: 31539748
[TBL] [Abstract][Full Text] [Related]
33. Discovery of 4-methyl-3-(pyridin-2-ylamino)benzamide derivatives as C-Abl inhibitors with potential neuroprotective effect.
Yang Z; Ai Y; Wan S; Yang Z; Li H; Li Z; Huang C; Zhang L; Li M; Zhang J; Zhang T
Bioorg Med Chem; 2022 Nov; 74():117069. PubMed ID: 36283251
[TBL] [Abstract][Full Text] [Related]
34. Novel piperazine based benzamide derivatives as potential anti-glioblastoma agents inhibiting cell proliferation and cell cycle progression.
Lu Y; Feng Y; Li Z; Li J; Zhang H; Hu X; Jiang W; Shi T; Wang Z
Eur J Med Chem; 2022 Jan; 227():113908. PubMed ID: 34656900
[TBL] [Abstract][Full Text] [Related]
35. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
Chang J; Ren H; Zhao M; Chong Y; Zhao W; He Y; Zhao Y; Zhang H; Qi C
Eur J Med Chem; 2017 Sep; 138():669-688. PubMed ID: 28711702
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of novel 4-phenoxypyridine based 3-oxo-3,4-dihydroquinoxaline-2-carboxamide derivatives as potential c-Met kinase inhibitors.
Wang Z; Shi J; Zhu X; Zhao W; Gong Y; Hao X; Hou Y; Liu Y; Ding S; Liu J; Chen Y
Bioorg Chem; 2020 Dec; 105():104371. PubMed ID: 33075664
[TBL] [Abstract][Full Text] [Related]
37. Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Pollack IF; Erff M; Bom D; Burke TG; Strode JT; Curran DP
Cancer Res; 1999 Oct; 59(19):4898-905. PubMed ID: 10519402
[TBL] [Abstract][Full Text] [Related]
38. In silico, synthesis and anticancer evaluation of benzamide tryptamine derivatives as novel eEF2K inhibitors.
Liu Z; Jiang A; Wang Y; Xu P; Zhang Q; Wang Y; He S; Wang N; Jin H; Zhang B
Bioorg Med Chem Lett; 2022 Jul; 67():128759. PubMed ID: 35483594
[TBL] [Abstract][Full Text] [Related]
39. Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.
Koul D; Wang S; Wu S; Saito N; Zheng S; Gao F; Kaul I; Setoguchi M; Nakayama K; Koyama K; Shiose Y; Sulman EP; Hirota Y; Yung WKA
Oncotarget; 2017 Mar; 8(13):21741-21753. PubMed ID: 28423515
[TBL] [Abstract][Full Text] [Related]
40. Novel bexarotene derivatives: Synthesis and cytotoxicity evaluation for glioma cells in 2D and 3D in vitro models.
Gretskaya NM; Gamisonia AM; Dudina PV; Zakharov SS; Sherstyanykh G; Akasov R; Burov S; Serkov IV; Akimov MG; Bezuglov VV; Markvicheva E
Eur J Pharmacol; 2020 Sep; 883():173346. PubMed ID: 32659303
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
